BioNTech SE (BNTX) Gross Margin (2018 - 2025)

BioNTech SE has disclosed Gross Margin across 8 years of filings, most recently posting 63.27% for Q4 2025.

• Gross Margin for Q4 2025 came in at 63.27%, down 3672.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 74.31% (down 2567.0% YoY), and the FY2025 annual result was 754.59%, down 83492.0% from the prior year.
• Gross Margin came in at 63.27% for Q4 2025 at BioNTech SE, down from 90.24% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 99.99% in Q4 2024 to a low of 82891.6% in Q1 2021.
• The 5-year median for Gross Margin is 79.9% (2021), against an average of 4166.71%.
• Across the five-year window, Gross Margin sank 8297038 bps in 2021 and soared 8297130 bps in 2022, its largest moves.
• BioNTech SE's Gross Margin stood at 89.46% in 2021, then increased by 7 bps to 95.71% in 2022, then retreated by 8 bps to 87.89% in 2023, then increased by 14 bps to 99.99% in 2024, then slumped by 37 bps to 63.27% in 2025.
• The last three Gross Margin figures came in at 63.27% (Q4 2025), 90.24% (Q3 2025), and 879.49% (Q2 2025), per Business Quant data.